GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?

范式转换 神经科学 B2受体 受体 医学 生物 内科学 哲学 缓激肽 认识论
作者
Abdelilah Arredouani
出处
期刊:Pharmacology & Therapeutics [Elsevier BV]
卷期号:269: 108824-108824 被引量:26
标识
DOI:10.1016/j.pharmthera.2025.108824
摘要

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as groundbreaking therapeutic agents in managing a spectrum of metabolic disorders, demonstrating remarkable efficacy across multiple organ systems and disease states. These compounds are not only well-established in the treatment of type 2 diabetes (T2D) and obesity-conditions for which they have received widespread approval-but also exhibit promising potential in addressing cardiovascular disease (CVD) and Metabolic dysfunction-associated steatotic liver disease (MASLD). Recent investigations have begun to illuminate the utility of GLP-1RAs in the management of type 1 diabetes (T1D), as well as neurodegenerative disorders such as Alzheimer's and Parkinson's disease and various behavioral disorders. A plethora of clinical trials have consistently validated the capacity of GLP-1RAs to improve glycemic control, promote weight loss, and mitigate cardiovascular risk factors in individuals with T2D and obesity. While their application in T1D remains limited due to safety concerns-particularly regarding the risks of hypoglycemia and hyperglycemic ketoacidosis-emerging data suggest that GLP-1RAs may offer hepatoprotective benefits, potentially reducing liver fat content and decelerating the progression of MASLD. The neuroprotective attributes of GLP-1 RAs have garnered significant interest, with research indicating their potential to alleviate cognitive decline associated with neurodegenerative diseases. Furthermore, preliminary findings highlight the role of GLP-1 RAs in addressing behavioral disorders, emphasizing their extensive therapeutic promise. This comprehensive review synthesizes the current evidence supporting the diverse therapeutic applications of GLP-1RAs, positioning them as "magic drug" therapies for metabolic and neurological disorders. As ongoing research continues to explore innovative applications and combinations of GLP-1RAs, the landscape of disease management in metabolic and neurological contexts is poised for transformative advancements. This review will also critically assess safety considerations and underscore the need for personalized treatment strategies to optimize patient outcomes in these complex and often comorbid conditions.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
张123完成签到,获得积分10
刚刚
1秒前
湘湘完成签到,获得积分10
1秒前
bybyca完成签到,获得积分10
1秒前
科研通AI6.4的应助被林鹿采纳,获得10
1秒前
nan11完成签到,获得积分10
2秒前
桐桐的应助被曾经又柔采纳,获得10
2秒前
2秒前
3秒前
一安完成签到,获得积分10
4秒前
Medici完成签到,获得积分10
5秒前
19978923839完成签到,获得积分10
5秒前
萝卜大王完成签到,获得积分20
5秒前
5秒前
艾叶发布了新的文献求助10
6秒前
6秒前
6秒前
6秒前
7秒前
风趣之云完成签到 ,获得积分10
7秒前
jja881完成签到,获得积分10
8秒前
九司完成签到,获得积分10
8秒前
Xk发布了新的文献求助10
8秒前
9秒前
zhumeili完成签到,获得积分10
10秒前
未白发布了新的文献求助10
10秒前
misscloud发布了新的文献求助10
10秒前
人间慈悲的应助被西西采纳,获得10
10秒前
cz完成签到 ,获得积分10
11秒前
11秒前
123131发布了新的文献求助10
11秒前
13秒前
lindollar发布了新的文献求助10
13秒前
搞怪的老九的应助被小吴采纳,获得20
13秒前
zhumeili发布了新的文献求助10
13秒前
14秒前
September完成签到 ,获得积分10
14秒前
独特振家完成签到,获得积分10
14秒前
Edward完成签到,获得积分10
15秒前
Xie完成签到,获得积分20
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187226
求助须知:如何正确求助?哪些是违规求助? 9575395
关于积分的说明 21841040
捐赠科研通 7784958
什么是DOI,文献DOI怎么找? 3434935
关于科研通互助平台的介绍 2559355
邀请新用户注册赠送积分活动 2481808